Abstract
A clinical study on a new carbapenem antibiotic, meropenem (MEPM), was carried out in acute pediatric infections. MEPM was administered to 8 patients including 3 patientswith acute pneumonia, 2 with cervical lymphadenitis, 1 with acute tonsillitis, and 1 with cellulitis and 1 with sepsis.
The overall efficacy rate was 100%. As an adverse reaction, diarrhea was observed in 1 patient.
In clinical laboratory tests 1 patient was found to have S-GPT elevation which normalized after discontinuation of MEPM.
MEPM appears to be effective and safe drug for pediatric acute infections.
